» Articles » PMID: 37998798

Pharmacoepidemiological Analysis of Antibacterial Agents Used in a Provisional Hospital in Aktobe, Kazakhstan, in the Context of COVID-19: A Comparison with the Pre-Pandemic Period

Overview
Specialty Pharmacology
Date 2023 Nov 24
PMID 37998798
Authors
Affiliations
Soon will be listed here.
Abstract

In the context of the global spread of Coronavirus Disease 2019 (COVID-19), the issue of evaluating and optimizing the use of antibacterial drugs becomes especially relevant. The coronavirus pandemic has provided a unique opportunity to study the dynamics of the consumption of antibacterial agents and their impact on public health. The rational use of antibiotics is a key aspect of the fight against antimicrobial resistance, which makes this study particularly important. The aim of this study was to assess changes in the consumption of antibacterial drugs among patients hospitalized with COVID-19 during the peak of the 2020 pandemic and compare them with data from 2019 prior to the pandemic. This study collated data on antibacterial drug consumption in a regional hospital in Aktobe, which served a large population of patients during the pandemic. A pharmacoepidemiological study was conducted using the Anatomical Therapeutic Chemical (ATC)/Defined Daily Dose (DDD) methodology. The pharmacoepidemiological study using the international ATC/DDD methodology revealed a concerning pattern of irrational consumption of antibacterial drugs, including cephalosporins, azalides, second-generation fluoroquinolones, and systemic aminoglycosides in Aktobe. Among antibacterial drugs during the pandemic, the most significant increase in consumption was from the group of cephalosporins (19,043 DDD/100 bed-days). The share of their consumption was 35.4% of the total consumption of antibacterial drugs. Pharmacoepidemiological studies using the international methodology ATC/DDD showed an alarming picture of irrational consumption of antibacterial drugs of the group of cephalosporins, azalides, fluoroquinolones, and aminoglycosides in Aktobe, and, in this case, excessive use of the identified antibiotics raises concerns about the possibility of increasing the problem of resistance to microbes.

Citing Articles

National trends in Azithromycin consumption during 2017-2023 in Kazakhstan: impact of the COVID-19 pandemic and the imperative for enhanced clinical guidelines.

Kassym L, Kussainova A, Semenov D, Aimurziyeva A, Uzbekova S, Semenova Y Sci Rep. 2025; 15(1):6309.

PMID: 39984711 PMC: 11845685. DOI: 10.1038/s41598-025-91216-4.


Evaluation of a national framework for rational use of medicines in Kazakhstan and its role in improving medicine use practices at the organizational and national levels.

Zhussupova G, Aiypkhanova A, Zhaldybayeva S, Satmbekova D, Akhayeva T, Kaliyeva S BMC Health Serv Res. 2025; 25(1):49.

PMID: 39789630 PMC: 11721059. DOI: 10.1186/s12913-024-12172-9.


A Nationwide Evaluation of Antibiotic Consumption in Kazakhstan from 2019 to 2023.

Semenova Y, Yergaliyeva A, Aimurziyeva A, Manatova A, Kuntuganova A, Makalkina L Antibiotics (Basel). 2025; 13(12.

PMID: 39766513 PMC: 11672648. DOI: 10.3390/antibiotics13121123.


Point-Prevalence Survey of Antimicrobial Use and Healthcare-Associated Infections in Four Acute Care Hospitals in Kazakhstan.

Semenova Y, Yessmagambetova A, Akhmetova Z, Smagul M, Zharylkassynova A, Aubakirova B Antibiotics (Basel). 2024; 13(10).

PMID: 39452247 PMC: 11505419. DOI: 10.3390/antibiotics13100981.


Consumption Trends of Antifungal and Antiprotozoal Agents for Human Systemic Use in Kazakhstan from 2017 to 2023.

Semenova Y, Kussainova A, Kassym L, Aimurziyeva A, Semenov D, Lim L Antibiotics (Basel). 2024; 13(9).

PMID: 39335029 PMC: 11440096. DOI: 10.3390/antibiotics13090857.


References
1.
Grau S, Hernandez S, Echeverria-Esnal D, Almendral A, Ferrer R, Limon E . Antimicrobial Consumption among 66 Acute Care Hospitals in Catalonia: Impact of the COVID-19 Pandemic. Antibiotics (Basel). 2021; 10(8). PMC: 8388964. DOI: 10.3390/antibiotics10080943. View

2.
Zhussupova G, Skvirskaya G, Reshetnikov V, Dragojevic-Simic V, Rancic N, Utepova D . The Evaluation of Antibiotic Consumption at the Inpatient Level in Kazakhstan from 2011 to 2018. Antibiotics (Basel). 2020; 9(2). PMC: 7168313. DOI: 10.3390/antibiotics9020057. View

3.
Lane J, Weaver J, Kostka K, Duarte-Salles T, Abrahao M, Alghoul H . Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol. 2020; 2(11):e698-e711. PMC: 7442425. DOI: 10.1016/S2665-9913(20)30276-9. View

4.
Ul Mustafa Z, Salman M, Aldeyab M, Kow C, Hasan S . Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan. SN Compr Clin Med. 2021; 3(8):1691-1695. PMC: 8162632. DOI: 10.1007/s42399-021-00966-5. View

5.
Sommet A . Interest of pharmacoepidemiology for the study of antibiotic drugs. Therapie. 2019; 74(2):249-253. DOI: 10.1016/j.therap.2018.10.005. View